Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Starpharma: A Buying Opportunity?

June 22nd, 2006

Starpharma: A Buying Opportunity?

Abstract:
Jack Uldrich: Yesterday, shares of Starpharma’s ADR (Advance Deposit Receipts) plummetted 25 percent on no discernible news. I was surprised and disappointed by the drop — especially because I had just bought more shares the other day when the stock (Nasdaq: SPHRY) was trading at $3.50 and I didn’t think it could go any lower.

Source:
NanoNovus

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Starpharma

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

Using quantum Parrondo’s random walks for encryption: Asst Prof Kang Hao Cheong and his research team from SUTD have set out to apply concepts from quantum Parrondo’s paradox in search of a working protocol for semiclassical encryption October 15th, 2021

Cellular environments shape molecular architecture: Researchers glean a more complete picture of a structure called the nuclear pore complex by studying it directly inside cells October 15th, 2021

How to program DNA robots to poke and prod cell membranes: A discovery of how to build little blocks out of DNA and get them to stick to lipids has implications for biosensing and mRNA vaccines October 15th, 2021

Molecular Sciences Software Institute receives $15 million grant from National Science Foundation October 15th, 2021

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project